UY34132A - Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab. - Google Patents

Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.

Info

Publication number
UY34132A
UY34132A UY0001034132A UY34132A UY34132A UY 34132 A UY34132 A UY 34132A UY 0001034132 A UY0001034132 A UY 0001034132A UY 34132 A UY34132 A UY 34132A UY 34132 A UY34132 A UY 34132A
Authority
UY
Uruguay
Prior art keywords
pyridopirimidinone
malignal
neoplasias
bendamustine
pi3k
Prior art date
Application number
UY0001034132A
Other languages
English (en)
Inventor
Decillis Arthur
Lager Joanne
Zaks Tal
Original Assignee
Sanofi Sa
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Exelixis Inc filed Critical Sanofi Sa
Publication of UY34132A publication Critical patent/UY34132A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Containers Having Bodies Formed In One Piece (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un método para el tratamiento de cánceres incluyendo neoplasias malignas h ematológicas que comprende administrar un compuesto de Fórmula I, en combinación con uno o ambos de bendamustina y rituximab.
UY0001034132A 2011-06-15 2012-06-15 Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab. UY34132A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161497356P 2011-06-15 2011-06-15
US201161510324P 2011-07-21 2011-07-21
FR1255114 2012-06-01

Publications (1)

Publication Number Publication Date
UY34132A true UY34132A (es) 2013-01-31

Family

ID=47357478

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034132A UY34132A (es) 2011-06-15 2012-06-15 Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.

Country Status (9)

Country Link
US (1) US20140302012A1 (es)
EP (1) EP2793892A1 (es)
JP (1) JP2014517042A (es)
CN (1) CN103874494A (es)
AR (1) AR086955A1 (es)
RU (1) RU2014101071A (es)
TW (1) TW201306842A (es)
UY (1) UY34132A (es)
WO (1) WO2012174327A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2593090T3 (pl) 2010-07-16 2022-02-21 Exelixis, Inc. Kompozycje farmaceutyczne modulatora c-Met
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
ES2754973T5 (es) 2010-09-27 2023-03-13 Exelixis Inc Inhibidores duales de MET y VEGF para el tratamiento del cáncer de próstata resistente a la castración y metástasis óseas osteoblásticas
KR20210147117A (ko) 2011-02-10 2021-12-06 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
GEP201706678B (en) 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
EP2758057B1 (en) 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
BR112014009302B1 (pt) 2011-10-20 2020-04-28 Exelis Inc Us/Us processo para preparar derivados de quinolina
CN107375289A (zh) 2011-11-01 2017-11-24 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
TW201521792A (zh) * 2013-03-05 2015-06-16 Sanofi Sa ＰＩ３Ｋα抑制劑之錠劑調配物
UA119321C2 (uk) 2013-03-15 2019-06-10 Екселіксіс, Інк. Метаболіти n-(4-{[6,7-біс(метилокси)хінолін-4-іл]окси}феніл)-n'-(4-фторфеніл)циклопропан-1,1-дикарбоксаміду
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
CA3181899A1 (en) 2014-02-14 2015-08-20 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
SG11201610770PA (en) * 2014-07-04 2017-01-27 Lupin Ltd Quinolizinone derivatives as pi3k inhibitors
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CA2957466C (en) 2014-08-05 2023-10-17 Exelixis, Inc. Drug combinations to treat multiple myeloma
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3497103B1 (en) * 2016-08-15 2021-05-05 Pfizer Inc. Pyridopyrimdinone cdk2/4/6 inhibitors
CA3038895A1 (en) 2016-09-29 2018-04-05 Telefonaktiebolaget Lm Ericsson (Publ) Active time handling with 2-step granting

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519047A (ja) * 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
JP4718637B2 (ja) * 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用
EA020022B1 (ru) * 2007-04-10 2014-08-29 Экселиксис, Инк. Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
WO2012065019A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha

Also Published As

Publication number Publication date
AR086955A1 (es) 2014-02-05
TW201306842A (zh) 2013-02-16
JP2014517042A (ja) 2014-07-17
US20140302012A1 (en) 2014-10-09
EP2793892A1 (en) 2014-10-29
CN103874494A (zh) 2014-06-18
RU2014101071A (ru) 2015-07-20
WO2012174327A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2016002974A (es) Eteres de arilo y sus usos.
CL2015002932A1 (es) Inhibidores de proteína quinasa
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34045A (es) Derivados de imidazopiridina como inhibidores de pi3k
AR089993A1 (es) Macrociclos peptidomimeticos
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201400178A1 (ru) Лечение рака молочной железы
UY35500A (es) Indazoles sustituidos con heteroarilo
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY33925A (es) Inhibidores tricíclicos de quinasas
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34138A (es) Antagonistas de trpv4
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020